貨號：GS40211

Eglatoprutug (development code PRT3789) is an investigational, humanized immunoglobulin G1-kappa (IgG1κ) monoclonal antibody designed for targeted cancer therapy. Unlike most therapeutic antibodies that block signaling or engage immune cells, eglatoprutug is engineered as a monoclonal antibody-based degrader. Its core mechanism is to specifically bind to its target on the cancer cell surface, recruit the cell's natural protein disposal system, and thereby induce the targeted degradation of the oncogenic receptor, leading to its removal from the cancer cell.